Full text

Turn on search term navigation

© 2016. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Still, there is need for significant improvements in reliable and accurate diagnosis for Alzheimer’s disease (AD) at early stages. It is widely accepted that changes in the concentration and conformation of amyloid-β (Aβ) appear several years before the onset of first symptoms of cognitive impairment in AD patients. Because Aβ oligomers are possibly the major toxic species in AD, they are a promising biomarker candidate for the early diagnosis of the disease. To date, a variety of oligomer-specific assays have been developed, many of them ELISAs. Here, we demonstrate the sFIDA assay, a technology highly specific for Aβ oligomers developed towards single particle sensitivity. By spiking stabilized Aβ oligomers to buffer and to body fluids from control donors, we show that the sFIDA readout correlates with the applied concentration of stabilized oligomers diluted in buffer, cerebrospinal fluid (CSF), and blood plasma over several orders of magnitude. The lower limit of detection was calculated to be 22 fM of stabilized oligomers diluted in PBS, 18 fM in CSF and 14 fM in blood plasma.

Details

Title
Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay
Author
Kühbach, Katja; Hülsemann, Maren; Herrmann, Yvonne; Kravchenko, Kateryna; Kulawik, Andreas; Linnartz, Christina; Peters, Luriano; Wang, Kun; Willbold, Johannes; Willbold, Dieter; Bannach, Oliver
Section
Technology Report ARTICLE
Publication year
2016
Publication date
Jan 29, 2016
Publisher
Frontiers Research Foundation
ISSN
16624548
e-ISSN
1662453X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2305192029
Copyright
© 2016. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.